RBDCOV project | Website

April 5, 2022

We are pleased to announce that the RBDCOV project website has been launched!!

RBDCOV is a project that aims to test the efficacy, tolerability and safety of the HIPRA’s vaccine against the different variants of COVID-19. The COVID-19 vaccine being developed by HIPRA is an adjuvanted recombinant protein vaccine, based on a receptor binding domain (RBD) fusion heterodimer containing variants B.1.1.7 (alpha) and B.1.351 (beta) of SARS-CoV-2.

The initiative is an innovative vaccine-focused research project that brings together the expertise of a number of European groups and companies in rational design of animal and human vaccine immunogens, vaccine manufacturing, distribution and commercialisation, cellular and humoral immune responses, clinical trials, regulatory issues, stakeholders involvement and patients perspective. Asphalion is proud regulatory partner of the project.

Check the website to get to know more about this HORIZON project and for regular updates as the project progresses.

For further information: info@asphalion.com

 

 

 

Search News & Events

  • Filter by category

Share

Related news and events

RBDCOV | Project extension

The European Commission has granted a fifteen-month extension to the EU-funded RBDCOV project, extending the journey to August 31, 2025. This extra time is crucial

VIDEO | FORCE REPAIR animated video

Take a look at this animated video about the FORCE Repair project! Asphalion is in charge of the Regulatory work package of this EU- funded

For further information

If you are interested in our services, or wish to get in touch for a general enquiry, please contact us for more information.

Fill the form and we will contact you as soon as possible.

You can also follow us on:

Schedule a Free Meeting

Schedule here a free 30-minutes meeting with one of our consultants and tell us about your project, challenges or doubts. 

We will be happy to assist you!

Schedule a meeting